Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study.
暂无分享,去创建一个
Eelco F. J. Meijer | M. Egger | A. Barać | P. Hamal | J. Meis | M. Bassetti | M. Arendrup | M. Hoenigl | R. Krause | M. Akova | A. Aujayeb | M. Backx | A. Tortorano | A. Goodman | A. Vena | D. Giacobbe | E. Roilides | C. Lass‐Flörl | E. van Wijngaerden | J. Steinmann | N. Khanna | K. Lagrou | S. Bretagne | O. Cornely | B. Willinger | A. Alastruey‐Izquierdo | S. Arikan‐Akdagli | T. Bicanic | J. Gangneux | J. Salmanton-García | P. Koehler | F. Lanternier | Ľ. Drgoňa | T. Freiberger | J. García Rodríguez | O. Sipahi | J. V. Van Praet | H. Guegan | Z. Ráčil | G. Desoubeaux | Ulrike Scharmann | J. Prattes | V. Arsić Arsenijević | R. Rautemaa‐Richardson | M. Mikulska | C. García-Vidal | M. Tumbarello | U. Sili | V. Özenci | R. Tomazin | D. Lockhart | Júlia Henriques | N. Erben | B. Denis | M. Narayanan | P. Hamal | J. Buil | C. Toscano | M. Samarkos | F. Danion | O. Turhan | M. Calbacho | O. Ozyurt | E. H. Akalın | J. Trauth | N. Klimko | B. Rogers | O. Blennow | T. Matos | I. Stoma | C. Logan | L. Loughlin | H. Hammarström | Alena Siváková | P. L. White | C. Milacek | Ang Li | Kai-Manuel Adam | J. Dávila-Valls | Thomas Longval | Harriet Jordan | Paloma García-Clemente | Christoph J. Zurl | N. D. de Jonge | Sonia Martín-Pérez | A. F. Talento | Deniz Akyol | P. García-Clemente | Yael Blankenheim | L. Rahimli | A. Gori | Maite Ruiz | Alba C Ruiz | V. Ferroni | Raphael Seufert | S. Martín-Pérez | Jochem B. Buil | E. Van Wijngaerden
[1] M. Hoenigl,et al. The current state of laboratory mycology and access to antifungal treatment in Europe: a European Confederation of Medical Mycology survey. , 2022, The Lancet. Microbe.
[2] D. Seidel,et al. COVID-19-associated fungal infections , 2022, Nature Microbiology.
[3] J. Perfect,et al. Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action , 2022, Expert opinion on investigational drugs.
[4] M. Hoenigl,et al. Let's talk about sex characteristics—As a risk factor for invasive fungal diseases , 2022, Mycoses.
[5] H. Tamim,et al. The Utility of EQUAL Candida Score in Predicting Mortality in Patients with Candidemia , 2022, Journal of fungi.
[6] A. Oliver,et al. Fluconazole-resistant Candida parapsilosis clonally related genotypes: first report proving the presence of endemic isolates harbouring the Y132F ERG11 gene substitution in Spain. , 2022, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[7] P. Ngamskulrungroj,et al. EQUAL Candida score, an effective tool for predicting the outcomes of Candida tropicalis candidaemia: A retrospective cohort study , 2022, Mycoses.
[8] M. Olsen,et al. Attributable Mortality of Candida Bloodstream Infections in the Modern Era: A Propensity Score Analysis. , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] J. Meis,et al. The current state of clinical mycology in Africa: a European Confederation of Medical Mycology and International Society for Human and Animal Mycology survey. , 2022, The Lancet. Microbe.
[10] M. Hoenigl,et al. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin , 2021, Drugs.
[11] L. Pagano,et al. EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19 , 2021, HemaSphere.
[12] Á. Soriano,et al. Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies , 2021, Open forum infectious diseases.
[13] D. Marriott,et al. Risk factors for candidaemia: A prospective multi‐centre case‐control study , 2020, Mycoses.
[14] H. Seifert,et al. Attributable mortality of candidemia after introduction of echinocandins , 2020, Mycoses.
[15] B. Tarai,et al. Multidrug-Resistant Candida auris Infections in Critically Ill Coronavirus Disease Patients, India, April–July 2020 , 2020, Emerging infectious diseases.
[16] Dustin L. Stwalley,et al. Effect of infectious disease consultation on mortality and treatment of patients with candida bloodstream infections: a retrospective, cohort study. , 2019, The Lancet. Infectious diseases.
[17] J. Bohlius,et al. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[18] P. Hamal,et al. ECMM CandiReg—A ready to use platform for outbreaks and epidemiological studies , 2019, Mycoses.
[19] M. Antonelli,et al. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project , 2019, Critical Care.
[20] D. Seidel,et al. Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: New leadership is about working together , 2018, Mycoses.
[21] B. Kullberg,et al. Invasive Candidiasis. , 2019, The New England journal of medicine.
[22] J. Meis,et al. Candida Score : An ECMM score derived from current guidelines to measure QUAlity of Clinical Candidaemia Management , 2018 .
[23] Felix Bongomin,et al. Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision , 2017, Journal of fungi.
[24] D. Seidel,et al. FungiScope™—Global Emerging Fungal Infection Registry , 2017, Mycoses.
[25] C. Steiner,et al. Epidemiology of Hospitalizations Associated with Invasive Candidiasis, United States, 2002–2012 , 2017, Emerging infectious diseases.
[26] J. Sobel,et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] P. Hamal,et al. Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM) (2006-2008). , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[28] J. Aguado,et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[29] Nicolas Papon,et al. Emerging and Emerged Pathogenic Candida Species: Beyond the Candida albicans Paradigm , 2013, PLoS pathogens.
[30] T. Calandra,et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[31] T. Calandra,et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[32] D. Harrison,et al. Risk factors for invasive fungal disease in critically ill adult patients: a systematic review , 2011, Critical care.
[33] O. Faure,et al. Epidemiology of Candidaemia in Europe: Results of 28-Month European Confederation of Medical Mycology (ECMM) Hospital-Based Surveillance Study , 2004, European Journal of Clinical Microbiology and Infectious Diseases.